Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
WOBURN, Mass. , Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App , now available for download from the Apple App store. The Quell Watch app gives a Quell user the ability to control and monitor their pain relief from their Apple
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
WOBURN, Mass. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269 titled “Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve
View HTML
Toggle Summary NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
WOBURN, Mass. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held September 11 - 13.  PAINWeek is the preferred resource in the U.S.
View HTML
Toggle Summary NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
WOBURN, Mass. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of diabetic peripheral neuropathy (DPN).  DPNCheck is a widely used point-of-care test that provides
View HTML
Toggle Summary NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
WOBURN, Mass. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH -funded, multi-site randomized controlled trial (RCT) of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced
View HTML
Toggle Summary Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free
WOBURN, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technology addresses knee pain. One-quarter of U.S. adults suffer from frequent knee pain, which decreases
View HTML
Toggle Summary NeuroMetrix Reports Q2 2020 Financial Results
WOBURN, Mass. , July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call
WOBURN, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on July
View HTML
Toggle Summary NeuroMetrix Reports DPNCheck® Expansion in China
WOBURN, Mass. , July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).
View HTML
Toggle Summary NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix
WOBURN, Mass. , June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets.
View HTML